Acute administration of SCH23390 increases D1 receptors on nonpyramidal neurons in rat mPFC

Synapse

Volumn 35, Issue 3, 2000, Pages 173-181

  Davidoff, Stephanie A ^a,b   Chu, Hung Ming ^a,b   Benes, Francine M ^a,b  

^a MCLEAN HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antipsychotic drug; APD; Clozapine; Dopamine; Medial prefrontal cortex; Nonpyramidal cells; Olanzapine; Pyramidal cells

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE 1 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; DRUG RECEPTOR BINDING; MALE; NEUROPIL; NONHUMAN; PERIKARYON; PREFRONTAL CORTEX; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; RAT; RECEPTOR DENSITY; RECEPTOR UPREGULATION;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANIMALS; DOPAMINE ANTAGONISTS; MALE; NEURONS; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1;

EID: 0342470948     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2396(20000301)35:3<173::AID-SYN2>3.0.CO;2-U     Document Type: Article

References (59)

1. 2 classification. Trends Pharmacol Sci 11:231-236.
2. Benes FM, Vincent SL, San Giovanni JP. 1989. High resolution imaging of receptor binding in analyzing neuropsychiatric diseases. Biotechniques 7:970-977.
3. Benes FM, Vincent SL, Molloy R. 1993. Dopamine-immunoreactive axon varicosities form nonrandom contacts with GABA-immunoreactive neurons of rat medial prefrontal cortex. Synapse 15:285-295.
4. Benes FM, Todtenkopf MS, Taylor JB. 1997. Differential distribution of tyrosine hydroxylase fibers on small and large neurons in layer II of anterior cingulate cortex of schizophrenic brain. Synapse 25:80-92.
5. 2 subtypes of dopamine receptors in rat brain. J Neurosci 6:3177-3188.
6. Bunney BS, Aghajanian GK. 1976. Dopamine and norepinephrine innervated cells in the rat prefrontal cortex: pharmacologic differentiation using microintophoretic techniques. Life Sci 19:1783-1789.
7. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT. 1996. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87-96.
8. Claghorn J, Honigfeld G, Abuzzahab FS, Wang R, Steinbook R, Tuason V, Klerman G. 1987. The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 7:377-384.
9. 1 dopamine receptor increase following chronic treatment with SCH23390. Eur J Pharmacol 109:127-128.
10. 1 receptor binding on pyramidal and non-pyramidal neurons. Synapse 28:83-90.
11. Dawson TM, Gehlert DR, McCabe RT, Barnett A, Wamsley JK. 1986. D-1 dopamine receptors in the rat brain: a quantitative autoradiographic analysis. J Neurosci 6:2352-2365.
12. 1-DA receptor antagonist SCH39166 on positive and negative symptoms in schizophrenia. Psychopharmacology 121:317-322.
13. 2 receptors. Neuroscience 19:125-137.
14. 1 receptors drugs that attenuate both positive and negative symptoms of schizophrenia? A pilot study in Java monkeys. Neuropsychopharmacology 2:191-199.
15. Emson PC, Koob GF, 1978. The origin and distribution of dopamine containing afferents to the rat frontal cortex. Brain Res 142:249-267.
16. Ferron A, Thierry AM, Le Douarin C, Glowinski J. 1984. Inhibitory influence of the mesocortical dopamine system on spontaneous activity or excitatory response induced from the thalamic mediodorsal nucleus in the rat medial prefrontal cortex. Brain Res 302:257-265.
17. Gellman RL, Aghajanian GK. 1993. Pyramidal cells in piriform cortex receive a convergence of inputs from monoamine activated GABAergic interneurons. Brain Res 600:63-73.
18. Gerlach J, Peacock L. 1995. New antipsychotics: the present status. Int Clin Psychopharmacol 10:39-48.
19. 1 receptors in the nigro-striatal system of rat. Eur J Pharmacol 245:139-145.
20. Godbout R, Mantz J, Pirot S, Glowinski J, Thierry AM. 1991. Inhibitory influence of the mesocortical dopaminergic neurons on their target cells: electrophysiological and pharmacological characterization. J Pharmacol Exp Ther 258:728-738.
21. Grace AA. 1991. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41:1-24.
22. 1 dopamine receptors down-regulates the Gsa subunit of G protein in SK-N-MC neuroblastoma cells. J Mol Neurosci 4:117-123.
23. 2-dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacology 11:245-256.
24. Herkenham M. 1988. Receptor autoradiography: optimizing anatomical resolution. In: Leslie FM, Altar CA, editors. Receptor localization ligand autoradiography. New York: Liss. p 37-38.
25. Huntley GW, Morrison JH, Prikhozhan A, Sealfon SC. 1992. Localization of multiple dopamine receptor subtype mRNAs in human and monkey cortex and striatum. Mol Brain Res 15:181.
26. Kebabian JW, Beaulieu M, Itoh Y. 1984. Pharmacological and biochemical evidence for the existence of two categories of dopamine receptor. Can J Neurol Sci 11:114.
27. 1 receptor antagonists: a quantitative autoradiographic study. Eur J Pharmacol 210:195-200.
28. 2 receptors in the primate prefrontal cortex. Proc Natl Acad Sci USA 91:4353-4356.
29. 5 receptors in the primate prefrontal cortex by chronic treatment with antipsychotic drugs. J Pharmacol Exp Ther 281:597-603.
30. Lindvall O, Bjorklund A. 1978. Anatomy of the dopaminergic neuron systems in the rat brain. In: Roberts PJ, Woodruff GN, Iversen LI, editors. Advances in biochemical psychopharmacology, vol 19. New York: Raven, p 1-23.
31. McGonigle P, Boyson SJ, Reuter S, Molinoff PB. 1989. Effects of chronic treatment with selective and nonselective antagonists on the subtypes of dopamine receptors. Synapse 3:74-82.
32. Meltzer HW. 1994. An overview of the mechanism of action of clozapine. J Clin Psychiatry 55:47-52.
33. Meltzer HY, Fibiger HC. 1996. Olanzapine: a new atypical antipsychotic drug. Neuropsychopharmacology 14:83-85.
34. Moore NA, Leander JD, Benvenga MJ, Gleason SD, Shannon H. 1997. Behavioral pharmacology of olanzapine: a novel antipsychotic drug. J Clin Psychiatry. 58 (Suppl.) 10:37-44.
35. 1 receptor. Eur J Pharmacol 267:7-19.
36. 2 receptor blockade. Life Sci 41:2279-2284.
37. 2 dopamine receptor agonists in the medial prefrontal cortex of young and aged Fischer 344 rats. J Pharmacol Exp Ther 254:539-545.
38. Penit-Soria J, Audinat E, Crepel F. 1987. Excitation of rat prefrontal cortical neurons by dopamine: an in vitro electrophysiological study. Brain Res 425:263-274.
39. Peterson SL, St Mary JS, Harding NR. 1987. Cis-flupentixol antagonism of the rat prefrontal cortex neuronal response to apomorphine and ventral tegmental area input. Brain Res Bull 24:267-273.
40. Peterson SL, Olsta SA, Matthews RT. 1990. Cocaine enhances medial prefrontal cortex neuron response to ventral tegmental area activation. Brain Res Bull 18:723-729.
41. Pirot S, Godbout R, Mantz J, Tassin JP, Glowinski J, Thierry AM. 1992. Inhibitory effects of ventral tegmental area stimulation on the activity of prefrontal cortical neurons: evidence for the involvement of both dopaminergic and GABAergic components. Neuroscience 49:857-865.
42. 1 dopamine receptors. Eur J Pharmacol 118:367-270.
43. 3H] GABA on rat prefrontal cortex slices. Neuroscience 42:61-71.
44. 2 receptors in the cerebral cortex of rats, cats, and monkeys. J Comp Neurol 286:409-426.
45. Roth RH, Tam SY, Ida Y, Yang JX, Deutch AY. 1988. Stress and the mesocorticolimbic dopamine systems. Ann NY Acad Sci 537:138-147.
46. See RE, Toga AW, Ellison G. 1990. Autoradiographic analysis of regional alterations in brain receptors following chronic administration and withdrawal of typical and atypical neuroleptics. J Neural Transm 82:93-109.
47. Seeman P. 1993. Receptor tables, vol 2. Drug dissociation constants for neuroreceptors and transporters. Toronto: SC Research.
48. Sesack SR, Bunny BS. 1989. Pharmacological characterization of the receptor mediating electrophysiological responses to dopamine in the rat medial prefrontal cortex: a microiontophoretic study. J Pharmacol Exp Ther 248:1323-1333.
49. Shi WX, Zheng P, Liang XF, Bunney BS. 1997. Characterization of dopamine-induced depolarization of prefrontal cortical neurons. Synapse 26:415-422.
50. Taylor MA, Abrahms R. 1984. Cognitive impairment in schizophrenia. Am J Psychiatry 141:196-201.
51. Thierry AM, Tassin JP, Blanc G, Glowinsky J. 1976. Selective activation of the mesocortical DA system by stress. Nature 263:242-244.
52. Van Eden CG, Hoorneman EMD, Buijs RM, Matthijjsen MAH, Gefard M, Uylings HBM. 1987. Immunocytochemical localization of dopamine in the prefrontal cortex of the rat at the light and electron microscopic level. Neuroscience 22:849-862.
53. Verney C, Alvarez C, Gerrard M, Berger B. 1990. Ultrastructural double-labelling study of dopamine terminals and GABA-containing neurons in rat anteromedial cortex. Eur J Neurosci 2:960-972.
54. 2 receptors in rat medial prefrontal cortex. J Neurosci 13:2551-2564.
55. 2 receptors in rat medial prefrontal cortex. Synapse 19:112-120.
56. Weibel ER. 1979. Practical methods for biological morphometry. Stereological methods, vol 1. New York: Academic Press, p 63-100.
57. Weinberger DR. 1988. Schizophrenia and the frontal lobe. Trends Neurosci 11:367-370.
58. 1 receptors in prefrontal cortex. Nature (Lond) 376:572-575.
59. Yang CR, Mogenson GJ. 1990. Dopaminergic modulation of cholinergic responses in rat medial prefrontal cortex: an electrophysiological study. Brain Res 524:271-281.